Myelin repair in neuromyelitis optica spectrum disorders: Mechanisms and interventions.
ABSTRACT: Neuromyelitis optica spectrum disorder is a severe autoimmune astrocytopathy of the central nervous system that is primarily driven by pathogenic aquaporin-4-targeted autoantibody immunoglobulin G. Although current immunotherapies substantially reduce relapse rates, the majority of patients still develop irreversible neurological disability, a consequence predominantly attributed to the failure of endogenous remyelination. Unlike multiple sclerosis, where demyelination is a primary event, myelin injury in neuromyelitis optica spectrum disorder is a secondary phenomenon arising from aquaporin-4-IgG-mediated astrocyte destruction. This fundamental difference creates a uniquely hostile repair microenvironment characterized by disruption of the astrocyte-oligodendrocyte axis, persistent chronic inflammation, and intrinsic oligodendrocyte precursor cell dysfunction. In this review, we systematically examine the pathological factors that impede myelin repair in neuromyelitis optica spectrum disorder, focusing on three interconnected barriers: (1) the loss of astrocyte-derived trophic and metabolic support for oligodendrocyte precursor cells; (2) the sustained presence of proinflammatory cytokines and complement fragments (C3a and C5a) that aberrantly activate inhibitory signaling pathways such as Wnt/β-catenin and Notch signaling and suppress proregenerative pathways such as mechanistic target of rapamycin complex 1; and (3) cell-intrinsic defects in oligodendrocyte precursor cells, including senescence, epigenetic silencing of myelin genes, and differentiation arrest. Furthermore, we critically evaluate emerging therapeutic strategies designed to overcome these obstacles, including immunomodulation to foster a reparative microenvironment, pharmacological targeting of oligodendrocyte precursor cell differentiation pathways, astrocyte replacement or functional enhancement, cell-based therapies, and axonal protection. Given the multifactorial nature of repair failure in neuromyelitis optica spectrum disorder, we argue that future interventions must move beyond single-agent approaches toward rational combination regimens. This review provides an evidence-based framework for developing targeted repair-promoting interventions, including small molecules, cell-based therapies, and neurotrophic approaches, while highlighting essential biomarkers and clinical trial endpoints needed to evaluate remyelination in vivo. Ultimately, this work shifts the therapeutic paradigm from passive disease control toward active neural restoration, offering actionable insights for clinicians to mitigate irreversible disability, personalize treatment strategies, and improve long-term outcomes for neuromyelitis optica spectrum disorder patients worldwide.
Authors
- Yan Yu (ORCID: https://orcid.org/0000-0003-0473-1794)
- Lin-Ming Zhang
- Ming-Wei Liu
- Zhang Yuan
Institutions
- Yunnan University (CN)
- Kunming Medical University (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-17
- DOI
- https://doi.org/10.4103/nrr.nrronline-d-26-00887
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00